At 09:48 am, the S&P BSE Healthcare index, the top gainer among sectoral indices, was up 2.9 per cent at 20,282 points, as compared to 0.4 per cent rise in the S&P BSE Sensex. The healthcare index hit a record high of 20,294 in intra-day trade today.
In a positive development for Lupin
and Cipla, Perrigo has announced a voluntary recall of its albuterol sulphate inhalation aerosols in the US over concerns that some units may not dispense properly due to clogging issues. Shares of Lupin
rallied 7 per cent to Rs 1,107, while Cipla
surged 5 per cent to Rs 790 on the BSE.
Dr Reddy's hit a fresh record high of Rs 5,090, up 6 per cent, after the company entered into a settlement agreement with Celgene Corp. In the past three days, the stock has gained 15 per cent after the firm said it has been roped-in by Russia-based Russian Direct Investment Fund (RDIF) to distribute 100 million Covid-19 vaccine doses in India.
Laurus Labs, too, hit a fresh record high of Rs 1,480 after rising 5 per cent tday. The stock has rallied 18 per cent thus far in the current week on expectation of strong earnings in July-September quarter (Q2FY21). The pharmaceutical company's stock was trading higher for the tenth straight day.
Meanwhile, the stock of Laurus Labs
will turn ex-date for 1:5 stock split on September 29, 2020. The company's board of directors has fixed September 30, 2020, as the record date for the sub-division of equity shares of the company from the existing face value of Rs 10 each to Rs 2 each. The company announced, on April 30, its stock split plan to make the stock more affordable for the small retail investors and increase liquidity.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.